NCT06624943View on ClinicalTrials.gov

Introducing Biosimilar Insulin Glargine to the Treatment Regimen of Children and Youth with Type 1 Diabetes in Mali

PHASE4CompletedINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

March 14, 2022

Primary Completion Date

May 5, 2023

Study Completion Date

May 5, 2023

Conditions
Type 1 Diabetes (T1D)
Interventions
DRUG

biosimilar insulin glargine

Once daily injection of biosimilar insulin glargine via reusable pen

Trial Locations (1)

Unknown

Hôpital du Mali, Bamako

All Listed Sponsors
collaborator

Sante Diabete Mali

OTHER

collaborator

Hospital of Mali

UNKNOWN

collaborator

Centre Hospitalier du Luxembourg

OTHER

collaborator

University Hospital, Geneva

OTHER

lead

Life for a Child Program, Diabetes Australia

OTHER